FORMA Therapeutics Closes $25.5 Million Series B

FORMA Therapeutics, a pre-clinical stage Cambridge, MA biopharma, has closed a Series B financing that raised $25.5 million. The round was led by new investor Lilly Ventures, while existing investors Novartis Option Fund and Bio*One Capital of Singapore participated. Forma has established a laboratory in Beijing at Tsinghua University, headed by Yigong Shi, PhD, a molecular biologist who is Chair of the School of Medicine there. The company also has labs in Singapore and Connecticut. More details...